Polymeric nanomedicine for cancer therapy

Jae Hyung Park; Seulki Lee; Jong Ho Kim; Kyeongsoon Park; Kwangmeyung Kim; Ick Chan Kwon

doi:10.1016/j.progpolymsci.2007.09.003

Polymeric nanomedicine for cancer therapy

Jae Hyung Park
, Seulki Lee
, Jong Ho Kim
, Kyeongsoon Park
, Kwangmeyung Kim
, Ick Chan Kwon^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

518 Citations (Scopus)

Abstract

Nanomedicine, an offshoot of nanotechnology, refers to highly specific, molecular-scale medical intervention for treating disease or repairing damaged tissues. In recent years, polymer-based nanomedicine, a field that includes the use of polymer-DNA complexes (polyplexes), polymer-drug conjugates, and polymer micelles bearing hydrophobic drugs, has received increasing attention for its ability to improve the efficacy of cancer therapeutics. Owing to their small size and excellent biocompatibility, nanosized polymer therapeutic agents can circulate in the bloodstream for long periods of time, allowing them to reach the target site. In addition, chemical modification of polymer therapeutic agents with ligands capable of specifically binding receptors that are over-expressed in cancer cells can markedly augment therapeutic efficiency. This review highlights the characteristics of cancer that provide nanodrug targeting opportunities and discusses rational approaches for future development of polymeric nanomedicines.

Original language	English
Pages (from-to)	113-137
Number of pages	25
Journal	Progress in Polymer Science (Oxford)
Volume	33
Issue number	1
DOIs	https://doi.org/10.1016/j.progpolymsci.2007.09.003
Publication status	Published - 2008 Jan

Bibliographical note

Funding Information:
This research was supported by the KIST intramural “Molecular Imaging Research Project” and by a Grant from the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (A062254B8150506N11C011B).

Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Angiogenesis
Cancer therapy
Drug carrier
Polymeric nanomedicine
Targeted delivery

ASJC Scopus subject areas

Ceramics and Composites
Surfaces and Interfaces
Polymers and Plastics
Organic Chemistry
Materials Chemistry

Access to Document

10.1016/j.progpolymsci.2007.09.003

Cite this

@article{25262a32e7854e5f8a8d62c4f5e064fb,

title = "Polymeric nanomedicine for cancer therapy",

abstract = "Nanomedicine, an offshoot of nanotechnology, refers to highly specific, molecular-scale medical intervention for treating disease or repairing damaged tissues. In recent years, polymer-based nanomedicine, a field that includes the use of polymer-DNA complexes (polyplexes), polymer-drug conjugates, and polymer micelles bearing hydrophobic drugs, has received increasing attention for its ability to improve the efficacy of cancer therapeutics. Owing to their small size and excellent biocompatibility, nanosized polymer therapeutic agents can circulate in the bloodstream for long periods of time, allowing them to reach the target site. In addition, chemical modification of polymer therapeutic agents with ligands capable of specifically binding receptors that are over-expressed in cancer cells can markedly augment therapeutic efficiency. This review highlights the characteristics of cancer that provide nanodrug targeting opportunities and discusses rational approaches for future development of polymeric nanomedicines.",

keywords = "Angiogenesis, Cancer therapy, Drug carrier, Polymeric nanomedicine, Targeted delivery",

author = "Park, \{Jae Hyung\} and Seulki Lee and Kim, \{Jong Ho\} and Kyeongsoon Park and Kwangmeyung Kim and Kwon, \{Ick Chan\}",

note = "Funding Information: This research was supported by the KIST intramural “Molecular Imaging Research Project” and by a Grant from the Korea Health 21 R\&D Project, Ministry of Health \& Welfare, Republic of Korea (A062254B8150506N11C011B). Copyright: Copyright 2008 Elsevier B.V., All rights reserved.",

year = "2008",

month = jan,

doi = "10.1016/j.progpolymsci.2007.09.003",

language = "English",

volume = "33",

pages = "113--137",

journal = "Progress in Polymer Science (Oxford)",

issn = "0079-6700",

publisher = "Elsevier Ltd",

number = "1",

}

TY - JOUR

T1 - Polymeric nanomedicine for cancer therapy

AU - Park, Jae Hyung

AU - Lee, Seulki

AU - Kim, Jong Ho

AU - Park, Kyeongsoon

AU - Kim, Kwangmeyung

AU - Kwon, Ick Chan

N1 - Funding Information: This research was supported by the KIST intramural “Molecular Imaging Research Project” and by a Grant from the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (A062254B8150506N11C011B). Copyright: Copyright 2008 Elsevier B.V., All rights reserved.

PY - 2008/1

Y1 - 2008/1

N2 - Nanomedicine, an offshoot of nanotechnology, refers to highly specific, molecular-scale medical intervention for treating disease or repairing damaged tissues. In recent years, polymer-based nanomedicine, a field that includes the use of polymer-DNA complexes (polyplexes), polymer-drug conjugates, and polymer micelles bearing hydrophobic drugs, has received increasing attention for its ability to improve the efficacy of cancer therapeutics. Owing to their small size and excellent biocompatibility, nanosized polymer therapeutic agents can circulate in the bloodstream for long periods of time, allowing them to reach the target site. In addition, chemical modification of polymer therapeutic agents with ligands capable of specifically binding receptors that are over-expressed in cancer cells can markedly augment therapeutic efficiency. This review highlights the characteristics of cancer that provide nanodrug targeting opportunities and discusses rational approaches for future development of polymeric nanomedicines.

AB - Nanomedicine, an offshoot of nanotechnology, refers to highly specific, molecular-scale medical intervention for treating disease or repairing damaged tissues. In recent years, polymer-based nanomedicine, a field that includes the use of polymer-DNA complexes (polyplexes), polymer-drug conjugates, and polymer micelles bearing hydrophobic drugs, has received increasing attention for its ability to improve the efficacy of cancer therapeutics. Owing to their small size and excellent biocompatibility, nanosized polymer therapeutic agents can circulate in the bloodstream for long periods of time, allowing them to reach the target site. In addition, chemical modification of polymer therapeutic agents with ligands capable of specifically binding receptors that are over-expressed in cancer cells can markedly augment therapeutic efficiency. This review highlights the characteristics of cancer that provide nanodrug targeting opportunities and discusses rational approaches for future development of polymeric nanomedicines.

KW - Angiogenesis

KW - Cancer therapy

KW - Drug carrier

KW - Polymeric nanomedicine

KW - Targeted delivery

UR - https://www.scopus.com/pages/publications/37249068568

U2 - 10.1016/j.progpolymsci.2007.09.003

DO - 10.1016/j.progpolymsci.2007.09.003

M3 - Review article

AN - SCOPUS:37249068568

SN - 0079-6700

VL - 33

SP - 113

EP - 137

JO - Progress in Polymer Science (Oxford)

JF - Progress in Polymer Science (Oxford)

IS - 1

ER -

Polymeric nanomedicine for cancer therapy

Abstract

Bibliographical note

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this